OncXerna Therapeutics Doses First Patient in Phase II Trial Evaluating Navicixizumab Alone or in Combination with Chemotherapy in Patients with Select Advanced Solid Tumors

OncXerna Therapeutics, Inc. announced the initiation of dosing in a Phase II basket trial evaluating the anti-DLL4/VEGF bispecific antibody navicixizumab, alone or in combination with chemotherapy, in patients with select advanced solid tumors.